Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
56.6M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
40.4M
-
Shares change
-
+458K
-
Total reported value, excl. options
-
$414M
-
Value change
-
-$490K
-
Put/Call ratio
-
0.13
-
Number of buys
-
45
-
Number of sells
-
-36
-
Price
-
$10.26
Significant Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) as of Q4 2022
102 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.4M shares
of 56.6M outstanding shares and own 71.33% of the company stock.
Largest 10 shareholders include SR ONE CAPITAL MANAGEMENT, LP (6.53M shares), Cormorant Asset Management, LP (5.15M shares), BlackRock Inc. (3.51M shares), STATE STREET CORP (3.04M shares), RA CAPITAL MANAGEMENT, L.P. (2.97M shares), Logos Global Management LP (2.8M shares), CITADEL ADVISORS LLC (2.5M shares), Avoro Capital Advisors LLC (2.27M shares), VANGUARD GROUP INC (1.56M shares), and FMR LLC (1.12M shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.